Comparative Outcomes of Warfarin vs. Direct Oral Anticoagulants (DOACs) in Anticoagulant-Related Gastrointestinal Bleeding: A Single-Center Study

2024

Comparing Warfarin and DOACs for GI Bleeding

Sample size: 384 publication 10 minutes Evidence: high

Author Information

Author(s): Muacevic Alexander, Adler John R, Ullah Naqeeb, Arif Wajeeha, Khan Mohammad B, Aioby Heywad T, Raza Iram, Siddiq Ambar, Siddiq Urooj, Ahmad Jamil, Ghufran Muhammad Hamza, Jan Ayiz, Safdar Sundas, Hanfi Hanifullah, Zia Shahabuddin

Primary Institution: Lady Reading Hospital, Peshawar, PAK

Hypothesis

This study aimed to evaluate clinical outcomes and the effectiveness of anticoagulation reversal techniques in patients with anticoagulant-related GI bleeding in emergency settings.

Conclusion

DOACs offer better outcomes in bleeding control and mortality compared to warfarin in anticoagulant-related GI bleeding.

Supporting Evidence

Patients on DOACs achieved better bleeding control (83.33%) compared to those on warfarin (72.22%).
Mortality was lower in the DOAC group (4.90%) compared to the warfarin group (11.11%).
Patients on warfarin had longer hospital stays (6.89 days) compared to those on DOACs (5.52 days).
Time to intervention was shorter for DOACs (4.64 hours) than for warfarin (5.28 hours).

Takeaway

This study found that patients taking DOACs had fewer problems with bleeding and lower death rates than those taking warfarin.

Methodology

This prospective, observational study included patients aged 18 or older with GI bleeding on warfarin or DOACs, collecting key clinical data and tracking outcomes such as bleeding control and mortality.